Title: Bamlanivimab for treatment of COVID‐19 in solid organ transplant recipients: Early single‐center experience
Abstract: Clinical TransplantationVolume 35, Issue 4 e14245 LETTER TO THE EDITOR Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience Abhay Dhand, Abhay Dhand orcid.org/0000-0003-3527-1938 Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this authorStephen A. Lobo, Stephen A. Lobo Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this authorKevin Wolfe, Kevin Wolfe Department of Surgery, Westchester Medical Center, NY, USASearch for more papers by this authorNicholas Feola, Nicholas Feola Department of Pharmacy, Westchester Medical Center, NY, USASearch for more papers by this authorChristopher Nabors, Christopher Nabors Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this author Abhay Dhand, Abhay Dhand orcid.org/0000-0003-3527-1938 Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this authorStephen A. Lobo, Stephen A. Lobo Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this authorKevin Wolfe, Kevin Wolfe Department of Surgery, Westchester Medical Center, NY, USASearch for more papers by this authorNicholas Feola, Nicholas Feola Department of Pharmacy, Westchester Medical Center, NY, USASearch for more papers by this authorChristopher Nabors, Christopher Nabors Department of Medicine, Westchester Medical Center, NY, USASearch for more papers by this author First published: 17 February 2021 https://doi.org/10.1111/ctr.14245Citations: 25 Correspondence Abhay Dhand, BHC-Transplant Center, Westchester Medical Center, Valhalla, NY 10595, USA Email: [email protected] Funding information There was no funding (research or employment) for this submission. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US Epicenter. Am J Transplant. 2020; 20: 1800-1808. https://doi.org/10.1111/ajt.15941 10.1111/ajt.15941 CASPubMedWeb of Science®Google Scholar 2Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020;ciaa1097: https://doi.org/10.1093/cid/ciaa1097 10.1093/cid/ciaa1097 PubMedWeb of Science®Google Scholar 3 Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab; 2020. https://www.fda.gov/media/143603/download. Accessed November 14, 2020 Google Scholar 4Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2021; 384(3): 229-237. 10.1056/NEJMoa2029849 CASPubMedWeb of Science®Google Scholar 5Lundgren JD, Grund B, Barkauskas CE, et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine. 2020. http://dx.doi.org/10.1056/nejmoa2033130. Web of Science®Google Scholar Citing Literature Volume35, Issue4April 2021e14245 ReferencesRelatedInformation